Zogenix Stock

Zogenix Intangible Assets

Delisted

The Intangible Assets of Zogenix (ZGNX) as of Aug 7, 2026 is 90.67 M USD. In the previous year, Intangible Assets was 98.60 M USD — a change of -8.04% (lower).

Intangible Assets

90.67 MUSD

YoY

-8.04%

Last updated:

Intangible Assets of Zogenix is 2026 90.67 M USD. Intangible Assets of Zogenix was 2025 98.60 M USD. It decreases by -8.04% lower compared to the previous year.
Access this data via the Eulerpool API

Zogenix Stock analysis

What does Zogenix do? Zogenix Inc. is an American biotech company that specializes in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. The company was founded in 2006 and is headquartered in Emeryville, California. In 2009, Zogenix Inc. brought its first product to market, the prescription painkiller Zohydro. Shortly after, in 2012, the company announced the approval of Sumavel DosePro, an innovative injection technology for the treatment of migraines. In 2018, the company completed a merger with California-based Modis Therapeutics. Together, they are developing drugs for rare genetic metabolic disorders. Zogenix has a promising business model, focusing on research and development and the marketing of true innovations in the CNS and pain field. The company aims to revolutionize the medical market with its medications, rather than simply replacing existing drugs. For this reason, Zogenix collaborates closely with leading institutes and research facilities to identify and develop new active ingredients. Zogenix is divided into various business segments, each specializing in the development of new drugs and therapies. One of Zogenix's main products is the Sumavel DosePro injection technology, which allows for quick and effective treatment of migraine attacks. Another important business area for Zogenix is the development of medications and therapies for the treatment of neuropsychiatric disorders. This includes ZX008 (Fenfluramine), an investigational drug for the treatment of Dravet syndrome, a rare form of epilepsy. The medication has already been approved in Europe and is currently being reviewed in the United States. Zogenix also focuses on the development of therapies for opioid and opiate-related disorders, as well as pain management. This includes the product Zohydro, which is a long-acting opioid painkiller. Zogenix offers a variety of prescription drugs and therapies targeting various neurological disorders and pain syndromes. The company's products aim to alleviate symptoms and address the underlying causes of the diseases. In summary, Zogenix is a biotech company specializing in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. With a wide range of products and a promising business model, the company is focused on innovation in the medical industry. Zogenix Inc represents an important area of research and development for new medications in the future. Zogenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zogenix stock

Intangible Assets of Zogenix is 90.67 M USD in 2026.

Intangible Assets of Zogenix changed from 98.60 M USD to 90.67 M USD, representing a -8.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Zogenix since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Zogenix historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Zogenix

All Key Metrics — Zogenix